Advertisement

Clinical and Experimental Nephrology

, Volume 22, Issue 6, pp 1351–1359 | Cite as

Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b–4 stages chronic кidney disease patients: a randomized pilot study

  • Lyudmila Milovanova
  • Victor Fomin
  • Sergey Moiseev
  • Marina Taranova
  • Yury Milovanov
  • Lidia Lysenko (Kozlovskaya)
  • Vasiliy Kozlov
  • Elena Kozevnikova
  • Svetlana Milovanova
  • Marina Lebedeva
  • Vladimir Reshetnikov
Original Article
  • 122 Downloads

Abstract

Background

A low protein diet (LPD) with essential amino acid ketoanalogue supplementation (KA) may contribute in improving of chronic kidney disease (CKD), while the exact mechanisms of KA’s effect are not established yet. We have conducted a prospective, randomized, controlled comparative study of LPD + KA and LPD alone in relation to serum Klotho, FGF-23 levels in CKD patients.

Methods

79 non-diabetic CKD 3b–4 stage patients, compliant with LPD diet (0.6 g/kg of body weight/day), had been selected. The patients were randomized into two groups. The first group (42 patients) received LPD + КA. The second group (37 patients) continued the LРD alone. In addition to routine tests, serum Klotho, FGF-23 levels, as well as bioimpedance analysis, sphygmography (stiffness (augmentation) indices (AI), central (aortal) blood pressure) with a «SphygmaCor» device; echocardiography (valvular calcification score (VCS) and LVMMI), were performed.

Results

There were body mass indices’ decrease (p = 0.046), including muscle body mass in men (p = 0.027) and woman (p = 0.044) in the LPD group to the end of study (14th month). In addition, lower FGF-23 (p = 0.029), and higher sKlotho (p = 0.037) were detected in the LPD + KA group compared to the LPD one. The increase in AI (p = 0.034), VCS (p = 0.048), and LVMMI (p = 0.023) was detected more often in the LPD group at the end of study.

Conclusion

LPD + KA provides support for nutrition status and contributes to more efficient correction of FGF-23 and Klotho abnormalities that may result in cardiovascular calcification and cardiac remodeling decreasing in CKD. At the same time, a prolonged LPD alone may lead to malnutrition.

Keywords

Chronic kidney disease Essential amino acid ketoanalogues Fibroblast growth factor-23 (FGF-23) Serum alpha-Klotho (sKlotho) Cardiovascular calcification Cardiac remodeling 

Notes

Acknowledgements

This work was supported by the Russian Science Foundation (Grant No. 14-15-00947 2014).

Compliance with ethical standards

Ethical approval

The study was approved by the Institutional Review Board of the Sechenov First Moscow State Medical University (Protocol No. 06–14, 16.06.2014). All the patients provided written informed consent. All the described procedures were performed in accordance with the Helsinki Declaration.

Supplementary material

10157_2018_1591_MOESM1_ESM.doc (58 kb)
Supplementary material 1 (DOC 58 KB)

References

  1. 1.
    Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.CrossRefGoogle Scholar
  2. 2.
    Eckardt K-U, Kasiske BL, et al. KDIGO clinical practice guideline for the diagnosis, evolution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Elsevier. 2009;76:S1–130.CrossRefGoogle Scholar
  3. 3.
    Piccoli GB, Capizzi I, Vigotti FN, Leone F, D’Alessandro C, Giuffrida D, et al. Low protein diets in patients with chronic kidney disease: a bridge between mainstream and complementary-alternative medicines? BMC Nephrol. 2016;17:1–13.CrossRefGoogle Scholar
  4. 4.
    Rysz J, Franczyk B, Ciałkowska-Rysz A, Gluba-Brzózka A. The effect of diet on the survival of patients with chronic kidney disease. Nutrients. 2017;9(5):495.  https://doi.org/10.3390/nu9050495. ,.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Snelson M, Clarke RE, Coughlan MT. Stirring the pot: can dietary modification alleviate the burden of CKD? Nutrients. 2017; 9(3): 265.  https://doi.org/10.3390/nu9030265.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Di Iorio BV, De Nicola BR, Minutolo L, Zamboli R, Trucillo P. et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 2007;71(3):245–51.  https://doi.org/10.1038/sj.ki.5001955.CrossRefPubMedGoogle Scholar
  7. 7.
    Zha Y, Qian Q. Protein nutrition and malnutrition in CKD and ESRD. Nutrients. 2017;9(3):208.  https://doi.org/10.3390/nu9030208.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–92.CrossRefGoogle Scholar
  9. 9.
    Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol Am Soc Nephrol. 2011;22:124–36. https://doi.org/10.1681/ASN.2009121311.CrossRefGoogle Scholar
  10. 10.
    Seiler S, Rogacev KS, Roth HJ, Shafein P, Emrich I, Neuhaus S, et al. Associations of FGF-23 and sklotho with cardiovascular outcomes among patients with CKD stages 2–4. Clin J Am Soc Nephrol. 2014;9:1049–58.  https://doi.org/10.2215/CJN.07870713.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Krieger NS, Culbertson CD, Kyker-Snowman K, Bushinsky DA. Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am J Physiol Renal Physiol. 2012;303(3):431–6.  https://doi.org/10.1152/ajprenal.00199.2012.CrossRefGoogle Scholar
  12. 12.
    Dalton GD, Xie J, An S-W, Huang C-L. New insights into the mechanism of action of soluble klotho. Front Endocrinol (Lausann). 2017;8:323.  https://doi.org/10.3389/fendo.2017.00323.CrossRefGoogle Scholar
  13. 13.
    Bartali B, Semba RD, Araujo AB. Klotho, FGF21 and FGF23: novel pathways to musculoskeletal health? J Frailty Aging. 2013;2(4):179–83.  https://doi.org/10.14283/jfa.2013.26.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010;78:679–85.  https://doi.org/10.1038/ki.2010.194.CrossRefPubMedGoogle Scholar
  15. 15.
    Lu X, Hu MC. Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. Kidney Dis Karger Publ. 2016;17:1–9.  https://doi.org/10.1159/000452880.CrossRefGoogle Scholar
  16. 16.
    Kuczera P, Adamczak M, Wiecek A. Fibroblast growth factor-23—a potential uremic toxin. Toxins (Basel). 2016;8(12):369.  https://doi.org/10.3390/toxins8120369.CrossRefGoogle Scholar
  17. 17.
    Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370–8.CrossRefGoogle Scholar
  18. 18.
    Hu MC, Shiizaki K, Kuro-O M, Moe OW. Fibroblast growth factor 23 and klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013. p. 503–33.  https://doi.org/10.1146/annurev-physiol-030212-183727.CrossRefGoogle Scholar
  19. 19.
    Neyra JA, Hu MC. αKlotho and chronic kidney disease. Vitam Horm. 2016. p. 257–310.  https://doi.org/10.1016/bs.vh.2016.02.007.CrossRefGoogle Scholar
  20. 20.
    Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.CrossRefGoogle Scholar
  21. 21.
    Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the Hormone Klotho. Science. 2005;309:1829–33.CrossRefGoogle Scholar
  22. 22.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med Massachusetts Med Soc. 2004;351:1296–305.CrossRefGoogle Scholar
  23. 23.
    Hu MC, Kuro-o M, Moe OW. Secreted Klotho And Chronic Kidney disease. Adv Exp Med Biol. 2012;728:126–57.  https://doi.org/10.1007/978-1-4614-0887-1_9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hu M-C, Shi M, Cho HJ, Zhang J, Pavlenco A, Liu S, et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int. 2013;84:468–81.CrossRefGoogle Scholar
  25. 25.
    De Borst MH, Vervloet MG, Ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011;22:1603–9.  https://doi.org/10.1681/ASN.2010121251.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013.  https://doi.org/10.1093/eurheartj/eht151.CrossRefPubMedGoogle Scholar
  27. 27.
    Ermolenko VM, Volgina GV, Dobronravov VA, et al. National recommendations on mineral and bone disorders in chronic kidney disease. Russian Dialysis Society (May 2010).Nephrologia I Dialis. 2011;13(1):33–51.Google Scholar
  28. 28.
    Garneata L, Stancu A, Dragomir D, Stefan G, Mircescu G. Ketoanalogue-supplemented vegetarian very low–protein diet and CKD progression. J Am Soc Nephrol. 2016;27(7):2164–76.  https://doi.org/10.1681/ASN.2015040369.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kovesdy RCM,AS-F, Kalantar-Zadeh CP. K. Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials. J Cachexia Sarcopenia Muscle. 2018;9(2):235–45.  https://doi.org/10.1002/jcsm.12264.CrossRefPubMedGoogle Scholar
  30. 30.
    Milovanova LY, Mukhin NA, Kozlovskaya LV, Milovanov YS, Kiyakbaev GG, Rogova IV, et al. Decreased serum levels of klotho protein in chronic kidney disease patients: clinical importance. Vestn Ross Akad Meditsinskikh Nauk. 2016;71:288–96.  https://doi.org/10.15690/vramn581.CrossRefGoogle Scholar
  31. 31.
    Neyra JA, Hu MC. Potential application of klotho in human chronic kidney disease. Bone. 2017.  https://doi.org/10.1016/j.bone.2017.01.017.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Xie J, Cha S-K, An S-W, Kuro-o M, Birnbaumer L, Huang C-L. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun. 2012;3:1238.  https://doi.org/10.1038/ncomms2240.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    NasrAllah MM, El-Shehaby AR, Osman NA, Fayad T, Nassef A, Salem MM, et al. The association between fibroblast growth factor-23 and vascular calcification is mitigated by inflammation markers. Nephron Extra. 2013;3(1):106–12.  https://doi.org/10.1159/000356118.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Steitz SA, Speer MY, Curinga G, Yang H-Y, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147–54.CrossRefGoogle Scholar
  35. 35.
    Zhou D, Tan RJ, Fu H, Liu Y. Wnt/[beta]-catenin signaling in kidney injury and repair: a double-edged sword. Lab Invest. 2016;96:156–67.  https://doi.org/10.1038/labinvest.2015.153.CrossRefPubMedGoogle Scholar
  36. 36.
    Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, et al. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol. 2014;25:1760–73.  https://doi.org/10.1681/ASN.2013080818.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Lyudmila Milovanova
    • 1
    • 2
  • Victor Fomin
    • 1
    • 3
  • Sergey Moiseev
    • 1
    • 2
  • Marina Taranova
    • 1
    • 2
  • Yury Milovanov
    • 1
    • 2
  • Lidia Lysenko (Kozlovskaya)
    • 1
    • 2
  • Vasiliy Kozlov
    • 1
    • 4
  • Elena Kozevnikova
    • 1
    • 2
  • Svetlana Milovanova
    • 1
    • 2
  • Marina Lebedeva
    • 1
    • 2
  • Vladimir Reshetnikov
    • 1
    • 4
  1. 1.Sechenov First Moscow State Medical University (Sechenov University)MoscowRussian Federation
  2. 2.Clinic of Nephrology and Internal DiseasesMoscowRussian Federation
  3. 3.Department of Faculty Therapy No. 1MoscowRussian Federation
  4. 4.Department of Public Health and Health Care OrganizationMoscowRussian Federation

Personalised recommendations